STAT+: Roche’s TIGIT study was a bust. What’s the outlook for its next big bet?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
A few years back, TIGIT was hailed as the next blockbuster target for cancer immunotherapy. Based on early data, drugmakers were hopeful that blocking two checkpoint proteins on immune cells — TIGIT and PD-1/PD-L1 — would be more effective at killing tumors than just blocking one, potentially offering greater benefit for a wider circle of cancer patients.
But TIGIT has not lived up to the hype, at least not yet. The most recent setback occurred just last week, when Roche reported the failure of its anti-TIGIT antibody in a Phase 3 study involving patients with non-small cell lung cancer.
